Table 2. Primary Antibodies.
Final Concentration (µg/ml) | ||||||
Antibody | Clone/Code | Source | Isotype | ICC | WB | FC |
β actin | 1 | IgG | - | 2 | - | |
CD44S | 2C5 | 3 | IgG2A | 1 | 2 | 16.7 |
Exon v3 | 3G5 | 4 | IgG2b | 2 | 2 | 16.7 |
Exon v4 | VFF11 | 4 | IgG1 | 1 | 2 | 16.7 |
Exon v5 | VFF8 | 4 | IgG1 | 5 | 2 | 16.7 |
Exon v6 | 2F10 | 4 | IgG1 | 1 | 2 | 16.7 |
Exon v7 | VFF9 | 4 | IgG1 | 5 | 2 | 16.7 |
Exon v7/8 | VFF17 | 4 | IgG2b | 2 | 0.5 | 16.7 |
Exon v9 | 441V | 5 | IgG1 | 2 | 2 | 16.7 |
Exon v10 | VFF14 | 4 | IgG1 | 20 | 2 | 90 |
1 – Santa Cruz, USA, 2 – Dako Ltd, UK, 3 – R&D Systems, UK, 4 – Serotec, UK, 5 – AmsBiotech (Europe) Ltd.